×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Exchange
/
Drug Targets
🎯 Drug Targets
Browse 7 drug targets with druggability analysis, composite scores, and clinical context
7
Targets
0
High Druggability
0.56
Avg Score
15
Target Classes
Druggability Distribution
High:
0
Medium:
0
Low:
7
Unknown:
0
Avg druggability score:
0.381
Clinical Pipeline
Approved:
1
Phase III:
1
Phase II:
2
Phase I:
3
Preclinical:
0
Total compounds:
7
· Approved:
1
Search
Class
All Classes
Enzyme
(35)
Signaling Protein
(25)
Structural Protein
(17)
Protein
(16)
Gpcr
(13)
Ion Channel
(12)
Transcription Factor
(11)
Receptor
(11)
Ligand
(10)
Transporter
(8)
Epigenetic Regulator
(8)
Kinase
(7)
Protease
(4)
Other
(4)
Chaperone
(4)
Druggability
All Druggability
Low
(100)
Medium
(62)
High
(14)
Undruggable
(6)
other
(3)
Sort
Score
Druggability
Gene A-Z
Market Price
Filtered by: class=ion_channel, druggability=Low — 7 results
AQP1
Aquaporin-1
Phase 4
Ion Channel
Low Druggability
Score
0.62
Drug.
0.39
Safety
0.50
Drugs
1
Hyps
1
Papers
26
AQP1 functions as a water channel protein facilitating transmembrane water flux, with emerging evidence suggesting its involvement in neuroinflammatory processes and potential contribution to neuronal cell volume regulation and edema formation in neurodegenerative conditions. In the context of neurodegeneration, AQP1 may modulate neuronal and glial cell responses to oxidative stress, inflammation, and cellular metabolic perturbations, making it a potential strategic target for therapeutic intervention.
GJA1
Gap junction alpha-1 protein (Connexin 43)
Phase 2
Ion Channel
Low Druggability
Score
0.62
Drug.
0.36
Safety
0.50
Drugs
1
Hyps
3
Papers
54
Small molecule modulator of gap junction channel activity
MCOLN1
Mucolipin-1
Phase 1
Ion Channel
Low Druggability
Score
0.59
Drug.
0.41
Safety
0.30
Drugs
1
Hyps
1
Papers
28
Small molecule agonists or modulators of lysosomal calcium channel activity
PIEZO1
Piezo-type mechanosensitive ion channel component
Phase 1
Ion Channel
Low Druggability
Score
0.55
Drug.
0.42
Safety
0.40
Drugs
1
Hyps
4
Papers
61
Small molecule modulator of mechanosensitive ion channel activity
CHR2
Channelrhodopsin-2
Phase 2
Ion Channel
Low Druggability
Score
0.55
Drug.
0.33
Safety
0.80
Drugs
1
Hyps
1
Papers
18
CHR2 functions as a light-gated cation channel that opens in response to blue light (470nm), allowing depolarization through Na+ and Ca2+ influx. Therapeutic approaches would involve delivering CHR2 via gene therapy to degenerated neurons or photoreceptors, enabling light-dependent control of neural activity for vision restoration or neuromodulation applications.
MCU
Mitochondrial calcium uniporter
Phase 3
Ion Channel
Low Druggability
Score
0.51
Drug.
0.41
Safety
0.25
Drugs
1
Hyps
3
Papers
31
MCU inhibitors block the mitochondrial calcium uniporter channel, reducing excessive calcium accumulation in mitochondria that leads to oxidative stress, energy depletion, and cell death. This mechanism may protect against ischemic injury, neurodegeneration, and heart failure by preserving mitochondrial function and preventing apoptosis in calcium-sensitive tissues.
AQP4
Aquaporin-4
Phase 1
Ion Channel
Low Druggability
Score
0.46
Drug.
0.35
Safety
0.45
Drugs
1
Hyps
13
Papers
61
Water channel inhibitor or modulator